Loading viewer...
investor_presentation
Format: PDF investor_presentation
Corporate Corporate Lonza Reports Strong Momentum with Organic Growth of 8% Sales and 11% CORE EBITDA in H1 2018– Double -Digit Organic Sales Growth for Businesses Along the Healthcare Continuum Richard Ridinger –CEO Rodolfo Savitzky –CFO Half-Year Results 2018 I 25 July 2018
Lonza Reports Strong Momentum with Organic Growth
of 8% Sales and 11% CORE EBITDA in H1 2018–
Double -Digit Organic Sales Growth for Businesses
Along the Healthcare Continuum
Richard Ridinger –CEO
Rodolfo Savitzky –CFO
Half-Year Results 2018 I 25 July 2018 Agenda
Half-Year 2018 Summary
Financial Highlights
Specialty Ingredients
Outlook 2018 and Mid -Term Guidance 2022
Half-Year Results 2018 I 25 July 2018 2
Outperformance in Pharma & Biotech in H1 2018, with margins up 270
bps, was combined with strong positive momentum in the newly
formed Consumer Health division
Legacy Capsugel businesses, now well integrated into Lonza,
exceeded expectations for performance and synergistic potential in H1
Growth drivers in Consumer & Resources Protection added to robust
momentum; but H1 was negatively impacted by more mature, cyclical
parts of the portfolio
Water business only gained good momentum in May and June with
positive outlook from H2 2018 onward
Half-Year Results 2018 I 25 July 2018 Lonza Reports Strong Momentum in H1 2018 (1/2)
Healthcare continuum leads the way with double -digit organic sales growth
All major investments that have already been announced are
progressing as planned
Full-Year 2018 sales outlook was upgraded
Double -digit return on invested capital ( ROIC) Mid -Term Guidance
2022 target was announced
Capital Markets Day in September 2018 will provide further
Preview truncated — download the full document for the complete content.
investor_presentation
35 Pages
investor_presentation
15 Pages
L3Harris Technologies
investor_presentation
Broadstone Net Lease